Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649913 | 0.84 | BAZ2B (0.48) | GAAKMT2AMEN1 | |
| SCHEMBL2516540 | 0.83 | POLB (0.44) | GAAKMT2AMAP3K5CYP2C9KCNH2 | |
| SCHEMBL22572547 | 0.83 | MAP3K5 (0.41) | GAAKMT2AMAP3K5CYP2C9KCNH2 | |
| SCHEMBL23480806 | 0.83 | MAP3K5 (0.42) | GAAKMT2AMAP3K5CYP2C9KCNH2 | |
| SCHEMBL24158883 | 0.82 | CTSD (0.45) | GAAMAP3K5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL16464463 | 0.82 | GAA (0.44) | GAAADCY10MAP3K5CYP2C9KCNH2 | |
| SCHEMBL30556712 | 0.82 | GAA (0.38) | GAAKMT2AGLAADCY10MAP3K5 | |
| Hydrochloric Acid SCHEMBL29002478 | 0.81 | POLB (0.43) | GAAKMT2AMAP3K5CYP2C9KCNH2 | |
| SCHEMBL20524576 | 0.81 | GAA (0.39) | GAAKMT2AMAP3K5CYP2C9KCNH2 | |
| SCHEMBL1657677 | 0.81 | KMT2A (0.40) | GAAKMT2AGLAMAP3K5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20070196406-A1 | 1,3-Dimethylbutyl carboxanilides for controlling undesirable micro-organisms | BAYER CROPSCIENCE AG (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | GAA 1597/4885KMT2A 2445/4885GLA 2293/4885 |
| US-20070196406-A1 | 1,3-Dimethylbutyl carboxanilides for controlling undesirable micro-organisms | MCRS1, MRM1, PADI1 | GAA 1203/4885KMT2A 1139/4885GLA 1292/4885 |
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | GAA 137/4885KMT2A 710/4885GLA 321/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | GAA 2419/4885KMT2A 2686/4885GLA 2788/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | GAA 1597/4885KMT2A 2445/4885GLA 2293/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | GAA 1597/4885KMT2A 2445/4885GLA 2293/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | GAA 1597/4885KMT2A 2445/4885GLA 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.